Long-Term Outcomes of Recipients of Liver Transplants from Living Donors Treated with a Very Low-Calorie Diet
The increasing prevalence of steatotic liver disease (SLD) in potential living donors is concerning, as it limits donor’s availability amid rising demand. OPTIFAST very low-calorie diet (VLCD), a meal replacement product, effectively reduces weight and hepatic steatosis before transplantation. Howev...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Journal of Transplantation |
| Online Access: | http://dx.doi.org/10.1155/2024/9024204 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849402088643100672 |
|---|---|
| author | Hannah Wozniak Sara Naimimohasses Toru Goto Gonzalo Sapisochin Blayne Sayed Anand Ghanekar Mark Cattral Nazia Selzner |
| author_facet | Hannah Wozniak Sara Naimimohasses Toru Goto Gonzalo Sapisochin Blayne Sayed Anand Ghanekar Mark Cattral Nazia Selzner |
| author_sort | Hannah Wozniak |
| collection | DOAJ |
| description | The increasing prevalence of steatotic liver disease (SLD) in potential living donors is concerning, as it limits donor’s availability amid rising demand. OPTIFAST very low-calorie diet (VLCD), a meal replacement product, effectively reduces weight and hepatic steatosis before transplantation. However, data on the outcomes of recipients of VLCD-treated donors are lacking. We conducted a single-center, retrospective study on 199 living donor liver transplant recipients at Toronto General Hospital, Canada, between January 2015 and January 2020. We compared the 1-year posttransplant outcomes between recipients who received organs from donors treated with VLCD (N = 34) for either weight loss or steatosis reduction, with those who did not require treatment (N = 165). Our analysis revealed no statistically significant differences in the rates of postoperative complications (23% vs 32.4%, p=0.3) or intensive care unit stays (70.9% vs 70.6%, p=1) between recipients of non-VLCD and VLCD grafts. Following adjusted multivariate logistic regression, receipt of VLCD grafts was not associated with increased hospital length of stay. In addition, one-year mortality did not differ between the two groups (4.2% non-VLCD recipients vs 2.9% VLCD recipients, p=0.6). OPTIFAST VLCD treatment for liver donors demonstrates positive and safe outcomes in recipients, expanding the pool of potential living donors for increased organ availability. |
| format | Article |
| id | doaj-art-843e8cd9a20e46e29f45a0732e336bdb |
| institution | Kabale University |
| issn | 2090-0015 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Transplantation |
| spelling | doaj-art-843e8cd9a20e46e29f45a0732e336bdb2025-08-20T03:37:38ZengWileyJournal of Transplantation2090-00152024-01-01202410.1155/2024/9024204Long-Term Outcomes of Recipients of Liver Transplants from Living Donors Treated with a Very Low-Calorie DietHannah Wozniak0Sara Naimimohasses1Toru Goto2Gonzalo Sapisochin3Blayne Sayed4Anand Ghanekar5Mark Cattral6Nazia Selzner7Interdepartmental Division of Critical Care MedicineMulti-Organ Transplant ProgramMulti-Organ Transplant ProgramMulti-Organ Transplant ProgramMulti-Organ Transplant ProgramMulti-Organ Transplant ProgramMulti-Organ Transplant ProgramMulti-Organ Transplant ProgramThe increasing prevalence of steatotic liver disease (SLD) in potential living donors is concerning, as it limits donor’s availability amid rising demand. OPTIFAST very low-calorie diet (VLCD), a meal replacement product, effectively reduces weight and hepatic steatosis before transplantation. However, data on the outcomes of recipients of VLCD-treated donors are lacking. We conducted a single-center, retrospective study on 199 living donor liver transplant recipients at Toronto General Hospital, Canada, between January 2015 and January 2020. We compared the 1-year posttransplant outcomes between recipients who received organs from donors treated with VLCD (N = 34) for either weight loss or steatosis reduction, with those who did not require treatment (N = 165). Our analysis revealed no statistically significant differences in the rates of postoperative complications (23% vs 32.4%, p=0.3) or intensive care unit stays (70.9% vs 70.6%, p=1) between recipients of non-VLCD and VLCD grafts. Following adjusted multivariate logistic regression, receipt of VLCD grafts was not associated with increased hospital length of stay. In addition, one-year mortality did not differ between the two groups (4.2% non-VLCD recipients vs 2.9% VLCD recipients, p=0.6). OPTIFAST VLCD treatment for liver donors demonstrates positive and safe outcomes in recipients, expanding the pool of potential living donors for increased organ availability.http://dx.doi.org/10.1155/2024/9024204 |
| spellingShingle | Hannah Wozniak Sara Naimimohasses Toru Goto Gonzalo Sapisochin Blayne Sayed Anand Ghanekar Mark Cattral Nazia Selzner Long-Term Outcomes of Recipients of Liver Transplants from Living Donors Treated with a Very Low-Calorie Diet Journal of Transplantation |
| title | Long-Term Outcomes of Recipients of Liver Transplants from Living Donors Treated with a Very Low-Calorie Diet |
| title_full | Long-Term Outcomes of Recipients of Liver Transplants from Living Donors Treated with a Very Low-Calorie Diet |
| title_fullStr | Long-Term Outcomes of Recipients of Liver Transplants from Living Donors Treated with a Very Low-Calorie Diet |
| title_full_unstemmed | Long-Term Outcomes of Recipients of Liver Transplants from Living Donors Treated with a Very Low-Calorie Diet |
| title_short | Long-Term Outcomes of Recipients of Liver Transplants from Living Donors Treated with a Very Low-Calorie Diet |
| title_sort | long term outcomes of recipients of liver transplants from living donors treated with a very low calorie diet |
| url | http://dx.doi.org/10.1155/2024/9024204 |
| work_keys_str_mv | AT hannahwozniak longtermoutcomesofrecipientsoflivertransplantsfromlivingdonorstreatedwithaverylowcaloriediet AT saranaimimohasses longtermoutcomesofrecipientsoflivertransplantsfromlivingdonorstreatedwithaverylowcaloriediet AT torugoto longtermoutcomesofrecipientsoflivertransplantsfromlivingdonorstreatedwithaverylowcaloriediet AT gonzalosapisochin longtermoutcomesofrecipientsoflivertransplantsfromlivingdonorstreatedwithaverylowcaloriediet AT blaynesayed longtermoutcomesofrecipientsoflivertransplantsfromlivingdonorstreatedwithaverylowcaloriediet AT anandghanekar longtermoutcomesofrecipientsoflivertransplantsfromlivingdonorstreatedwithaverylowcaloriediet AT markcattral longtermoutcomesofrecipientsoflivertransplantsfromlivingdonorstreatedwithaverylowcaloriediet AT naziaselzner longtermoutcomesofrecipientsoflivertransplantsfromlivingdonorstreatedwithaverylowcaloriediet |